Does anyone have some dollar figures for the potential market size of each of our phase II trial drugs upon FDA approval? i.e the size of the lupus drug market, asthma and smokers cough?
Prana biotech might be world leaders in neurodegenerative drug development, but invion are very highly placed in autoimmune drug development IMO, so with such a vast difference in market cap, and results due for 2 phase II trials 1H 2014 (just like prana), I suppose it must be because our target drug market isn't that big, whereas Pranas Alzheimer's market is something like $10b. Also our vulnerable cash position is probably weighing on our market cap also I suppose. But i still can't believe our tiny market cap with results due out at any time
Add to My Watchlist
What is My Watchlist?
